RxDoctor Payments Data

Adrianna Weber, PA

Physician Assistant · South Daytona, FLNPI 1801343702

Payments from drug & device makers

$571in general payments, 2019–2025

Across 14 payments — averaging $40.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$213
  • Novo Nordisk$125
  • Boston Scientific$62
  • Novartis$55
  • Vanda Pharmaceuticals Inc.$45
  • Bayer$33
  • plus $38 from 2 others

What the payments were for

  • Food & beverage$571100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$571 in reported general payments places this provider in the 50th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$16,109
Medicare patients
89
Services billed
401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban60$80,320
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$57,769
XareltoRivaroxaban40$37,037
TresibaInsulin Degludec23$23,407
InvokanaCanagliflozin25$20,860
EntrestoSacubitril/Valsartan13$14,872
Tresiba Flextouch U-100Insulin Degludec17$10,666
Albuterol Sulfate HfaAlbuterol Sulfate146$8,550
Fluticasone-SalmeterolFluticasone Propion/Salmeterol30$5,270
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$3,941
Rosuvastatin Calcium515$2,964
Novolog FlexpenInsulin Aspart16$2,881
Ezetimibe281$2,762
Fenofibrate192$2,375
Atorvastatin Calcium424$2,368

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$19$80,32060 claims
Johnson & JohnsonXarelto, Invokana$18$57,89765 claims
Novo NordiskTresiba$125$23,40723 claims
NovartisEntresto$55$14,87213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in South Daytona

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →